WO2017158184A3 - Antivirale immuntherapie durch membranrezeptorligation - Google Patents
Antivirale immuntherapie durch membranrezeptorligation Download PDFInfo
- Publication number
- WO2017158184A3 WO2017158184A3 PCT/EP2017/056443 EP2017056443W WO2017158184A3 WO 2017158184 A3 WO2017158184 A3 WO 2017158184A3 EP 2017056443 W EP2017056443 W EP 2017056443W WO 2017158184 A3 WO2017158184 A3 WO 2017158184A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane receptor
- viral infection
- lymphocytes
- cytotoxic agent
- receptor ligation
- Prior art date
Links
- 102000006240 membrane receptors Human genes 0.000 title abstract 3
- 108020004084 membrane receptors Proteins 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 208000036142 Viral infection Diseases 0.000 abstract 4
- 229940127089 cytotoxic agent Drugs 0.000 abstract 4
- 239000002254 cytotoxic agent Substances 0.000 abstract 4
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 4
- 230000009385 viral infection Effects 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018134022A RU2773427C2 (ru) | 2016-03-18 | 2017-03-17 | Противовирусная иммунотерапия посредством лигирования мембранных рецепторов |
AU2017235611A AU2017235611B2 (en) | 2016-03-18 | 2017-03-17 | Antiviral immunotherapy by membrane receptor ligation |
JP2018549270A JP7303631B2 (ja) | 2016-03-18 | 2017-03-17 | 膜受容体への結合による抗ウイルス免疫療法 |
EP17711660.5A EP3430048A2 (de) | 2016-03-18 | 2017-03-17 | Antivirale immuntherapie durch membranrezeptorligation |
CN201780017932.9A CN109071661A (zh) | 2016-03-18 | 2017-03-17 | 通过膜受体连接的抗病毒免疫疗法 |
US16/131,325 US11208469B2 (en) | 2016-03-18 | 2018-09-14 | Antiviral immunotherapy by membrane receptor ligation |
US17/541,134 US20220153816A1 (en) | 2016-03-18 | 2021-12-02 | Antiviral immunotherapy by membrane receptor ligation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102016105069.5 | 2016-03-18 | ||
DE102016105069.5A DE102016105069A1 (de) | 2016-03-18 | 2016-03-18 | Antivirale Immuntherapie durch Membranrezeptorligation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/131,325 Continuation US11208469B2 (en) | 2016-03-18 | 2018-09-14 | Antiviral immunotherapy by membrane receptor ligation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017158184A2 WO2017158184A2 (de) | 2017-09-21 |
WO2017158184A3 true WO2017158184A3 (de) | 2017-11-09 |
Family
ID=58358614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/056443 WO2017158184A2 (de) | 2016-03-18 | 2017-03-17 | Antivirale immuntherapie durch membranrezeptorligation |
Country Status (7)
Country | Link |
---|---|
US (2) | US11208469B2 (de) |
EP (1) | EP3430048A2 (de) |
JP (1) | JP7303631B2 (de) |
CN (1) | CN109071661A (de) |
AU (1) | AU2017235611B2 (de) |
DE (1) | DE102016105069A1 (de) |
WO (1) | WO2017158184A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021296450A1 (en) | 2020-06-25 | 2022-10-20 | The Procter & Gamble Company | Aptamers for personal health care applications |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120141465A1 (en) * | 2006-10-04 | 2012-06-07 | La Jolla Institute For Allergy And Immunology | Virus vaccination and treatment methods with ox40 agonist compositions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE650020T1 (de) | 1993-10-20 | 1996-05-02 | Isuzu Ceramics Res Inst | Keramisches Heizelement und Herstellungsverfahren dafür. |
CA2321161C (en) | 1998-02-24 | 2011-12-20 | Andrew D. Weinberg | Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response |
DE60317677T2 (de) * | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
EP2650020B1 (de) | 2005-05-06 | 2016-08-24 | Providence Health & Services - Oregon | Trimeres OX40-Immunglobulin-Fusionsprotein und Verwendungsverfahren |
AR057253A1 (es) | 2005-12-16 | 2007-11-21 | Genentech Inc | Anticuerpos anti-ox40l y metodos que los utilizan |
AU2012282116B2 (en) | 2011-07-11 | 2016-07-07 | Ichnos Sciences SA | Antibodies that bind to OX40 and their uses |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
BR112015023862A2 (pt) | 2013-03-18 | 2017-10-24 | Biocerox Prod Bv | anticorpo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, método de realçar uma resposta imune, método de tratar câncer, composição farmacêutica, e, anticorpo agonístico isolado |
EP3083687A2 (de) | 2013-12-17 | 2016-10-26 | F. Hoffmann-La Roche AG | Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten |
CR20160500A (es) * | 2014-03-31 | 2016-12-14 | Genentech Inc | Anticuerpos anti-ox40 y métodos de uso |
WO2015153514A1 (en) * | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
JP6764474B2 (ja) * | 2015-09-25 | 2020-09-30 | ジェネンテック, インコーポレイテッド | 抗tigit抗体及び使用方法 |
-
2016
- 2016-03-18 DE DE102016105069.5A patent/DE102016105069A1/de active Pending
-
2017
- 2017-03-17 JP JP2018549270A patent/JP7303631B2/ja active Active
- 2017-03-17 WO PCT/EP2017/056443 patent/WO2017158184A2/de active Application Filing
- 2017-03-17 EP EP17711660.5A patent/EP3430048A2/de active Pending
- 2017-03-17 CN CN201780017932.9A patent/CN109071661A/zh active Pending
- 2017-03-17 AU AU2017235611A patent/AU2017235611B2/en active Active
-
2018
- 2018-09-14 US US16/131,325 patent/US11208469B2/en active Active
-
2021
- 2021-12-02 US US17/541,134 patent/US20220153816A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120141465A1 (en) * | 2006-10-04 | 2012-06-07 | La Jolla Institute For Allergy And Immunology | Virus vaccination and treatment methods with ox40 agonist compositions |
Non-Patent Citations (3)
Title |
---|
AMMARANOND PALANEE ET AL: "STUDY ON THE EXPRESSION OF CO-STIMULATORY MARKER CD134 ON CD4+ T CELLS IN HIV-1-INFECTED INDIVIDUALS", JOURNAL OF IMMUNOASSAY AND IMMUNOCHEMISTRY, vol. 33, no. 2, 1 April 2012 (2012-04-01), US, pages 195 - 202, XP055388096, ISSN: 1532-1819, DOI: 10.1080/15321819.2011.618861 * |
W. JIANG ET AL: "Cycling Memory CD4+ T Cells in HIV Disease Have a Diverse T Cell Receptor Repertoire and a Phenotype Consistent with Bystander Activation", JOURNAL OF VIROLOGY., vol. 88, no. 10, 15 May 2014 (2014-05-15), US, pages 5369 - 5380, XP055388160, ISSN: 0022-538X, DOI: 10.1128/JVI.00017-14 * |
WEINBERG A D ET AL: "Science gone translational: the OX40 agonist story", IMMUNOLOGICAL REVIEWS, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 244, no. 1, 1 November 2011 (2011-11-01), pages 218 - 231, XP002739167, ISSN: 0105-2896, [retrieved on 20111021], DOI: 10.1111/J.1600-065X.2011.01069.X * |
Also Published As
Publication number | Publication date |
---|---|
RU2018134022A3 (de) | 2020-04-20 |
US11208469B2 (en) | 2021-12-28 |
AU2017235611B2 (en) | 2020-05-28 |
DE102016105069A1 (de) | 2017-09-21 |
US20220153816A1 (en) | 2022-05-19 |
US20190077848A1 (en) | 2019-03-14 |
EP3430048A2 (de) | 2019-01-23 |
AU2017235611A1 (en) | 2018-10-04 |
CN109071661A (zh) | 2018-12-21 |
JP2019517995A (ja) | 2019-06-27 |
WO2017158184A2 (de) | 2017-09-21 |
RU2018134022A (ru) | 2020-04-20 |
JP7303631B2 (ja) | 2023-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500335A1 (en) | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection | |
JOP20210109A1 (ar) | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
NZ729150A (en) | Antiretroviral agents | |
PH12018501962A1 (en) | Stablizied soluble pre-fusion rsv f proteins | |
PH12019502201A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
PH12018502077A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
PH12017500571A1 (en) | Mono-or di-substituted indole derivatives as dengue viral replication inhibitors | |
PH12018500569A1 (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
CR20190531A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
PH12018500576A1 (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
MX2018011788A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
PH12017501272A1 (en) | Indole derivatives as dengue viral replication inhibitors | |
MX2019011608A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
MX2019013893A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
EP4311575A3 (de) | Methotrexat zur proliferativen vitreoretinopathie | |
WO2017158184A3 (de) | Antivirale immuntherapie durch membranrezeptorligation | |
PH12020550673A1 (en) | Pyrazolopyrimidines having activity against the respiratory syncytial virus (rsv) | |
MX2017002093A (es) | Terapia con anticuerpos para vih como sustituto de tratamiento. | |
WO2016180826A8 (en) | Influenza virus neutralizing peptidomimetic compounds | |
MY185672A (en) | Mono-or di-substituted indole derivatives as dengue viral replication inhibitors | |
WO2016036252A3 (en) | Hepatitis c virus specific antibody | |
EP3768681A4 (de) | Hemmung von nsmase zur behandlung von hiv-infektionen | |
MY197383A (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018549270 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017235611 Country of ref document: AU Date of ref document: 20170317 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017711660 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017711660 Country of ref document: EP Effective date: 20181018 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17711660 Country of ref document: EP Kind code of ref document: A2 |